Invalidation of a Commercially Available Human 5α-Dihydrotestosterone Immunoassay

September 2013 in “ Steroids ”

Joshua F. Yarrow, Darren T. Beck, Christine F. Conover, Luke A. Beggs, Bruce A. Goldberger, Stephen E. Borst

dihydrotestosterone DHT testosterone finasteride LC–MS/MS immunoassay Propecia

Studysummary This study found that a commonly-used DHT enzyme immunoassay shows significant cross-reactivity with testosterone, leading to inaccurate DHT measurements compared to a gold-standard LC–MS/MS method.

Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer

The study invalidated a commercially available dihydrotestosterone (DHT) immunoassay due to significant cross-reactivity with testosterone, which ranged from 18% to 99%. This cross-reactivity led to DHT concentrations being overestimated by 79% to over 1000% compared to the gold-standard LC–MS/MS method. The immunoassay failed to detect reductions in DHT following finasteride treatment, unlike LC–MS/MS. The study involved older hypogonadal men in a 12-month trial, highlighting that the immunoassay's results were not reliable for assessing DHT in biological fluids containing testosterone.

View this study on sciencedirect.com →

Discuss this study in the Community →

Research cited in this study

6 / 6 results

research Intracrine and Myotrophic Roles of 5α-Reductase and Androgens

35 citations , October 2011 in “Medicine and science in sports and exercise”

This review discusses the role of skeletal muscle in synthesizing bioactive androgens, highlighting that intramuscular androgens may influence muscle via intracrine action, but their precise function remains unclear.

research Anabolic Effects of Testosterone Are Preserved During Inhibition of 5α-Reductase

42 citations , May 2007 in “Endocrinology and metabolism/American journal of physiology: endocrinology and metabolism”

In this animal study, administering testosterone alongside a 5α-reductase inhibitor counteracted testosterone's effects on prostate enlargement while preserving its beneficial effects on muscle and bone.

research The Effect of 5α-Reductase Inhibition with Dutasteride and Finasteride on Semen Parameters and Serum Hormones in Healthy Men

195 citations , February 2007 in “The Journal of Clinical Endocrinology and Metabolism”

In this study, administering 5alpha-reductase inhibitors reduced dihydrotestosterone levels and was associated with mild, reversible decreases in semen parameters in healthy men.

research Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone

417 citations , February 2004 in “The Journal of Clinical Endocrinology and Metabolism”

This study found that testosterone therapy increased bone mineral density in older men with low testosterone, and combining it with finasteride may reduce prostate enlargement associated with testosterone treatment.

research 5alpha-Reductase: History and Clinical Importance

62 citations , January 2004 in “PubMed”

This review describes the shift in treating symptomatic benign prostatic hyperplasia from surgery to 5alpha-reductase inhibitor drugs, which may provide symptom relief and alter BPH's progression, but reports no new clinical results.

research Use of Finasteride in the Treatment of Men With Androgenetic Alopecia

38 citations , June 2003 in “Journal of Investigative Dermatology Symposium Proceedings”

This review summarizes existing research on the use of finasteride for treating androgenetic alopecia in men, reporting its effectiveness at 1 mg/day and a strong safety profile, but presents no new findings.